DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Down 5.7% Today

What is DENTSPLY SIRONA Inc.?

A global leader in dental products and technologies, Dentsply Sirona Inc. (XRAY) focuses on innovation in the digital dentistry market. In the recent quarter, the company reported revenue exceeding expectations, but adjusted EPS fell short of estimates.

Why is DENTSPLY SIRONA Inc. going down?

XRAY stock is down 5.7% on May 15, 2026 13:56

• The decline in Dentsply Sirona's stock (XRAY) today is linked to the earnings miss in Q1, despite surpassing revenue expectations.
• The market's negative response to the revised FY guidance is due to the company reducing its EPS outlook for the full year, suggesting potential challenges ahead.
• A rise in wholesale inflation to 6% annually as shown in the April PPI report has impacted healthcare companies like Dentsply Sirona, increasing operating costs and raising concerns about possible regulatory actions on drug pricing.
• Despite a significant drop in the stock price over the past year, assessments of the company's value indicate Dentsply Sirona may be undervalued, offering a different perspective on its future prospects.

XRAY Price Chart

XRAY Technical Analysis

XRAY News

Dentsply Sirona stock (US9839191015): Q1 earnings miss and updated FY guidance

Dentsply Sirona (XRAY) reported its Q1 2026 earnings, with adjusted EPS of $0.27, missing estimates by $0.01, though revenue of $880 million surpassed expectations. The company updated its full-year 2026 guidance for EPS to $1.40-$1.50 and revenue to $3.5-$3.6 billion. The article highlights Dentsply Sirona's position as a global leader in dental products and technologies, emphasizing recurring revenue from consumables, equipment sales, and the company's focus on innovation in a growing digital dentistry market.

https://www.ad-hoc-news.de/boerse/news/ueberblick/dentsply-sirona-stock-us9839191015-q1-earnings-miss-and-updated-fy/69336130

Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

Shares of Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics fell in the afternoon trading session following the release of the April PPI report, which indicated an acceleration in wholesale inflation to 6% annually. The report highlighted a significant rise in service-sector prices, creating headwinds for healthcare companies due to increased operating costs and potential regulatory intervention concerning drug pricing. Amidst this market reaction, Collegium Pharmaceutical's stock showed particular volatility but had previously seen a substantial gain six months prior due to strong Q3 2025 financial results.

https://www.tradingview.com/news/stockstory:5ad1425d2094b:0-thermo-fisher-dentsply-sirona-collegium-pharmaceutical-and-halozyme-therapeutics-stocks-trade-down-what-you-need-to-know/

UBS Group AG Grows Holdings in DENTSPLY SIRONA Inc. $XRAY

UBS Group AG significantly increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 63.7% in the fourth quarter, now holding 1.7 million shares valued at approximately $19.5 million. This increase occurred despite the company missing quarterly earnings estimates by a penny, though revenue exceeded expectations. Analyst sentiment remains cautious with a "Hold" consensus rating and an average price target of $13.82.

https://www.marketbeat.com/instant-alerts/filing-ubs-group-ag-grows-holdings-in-dentsply-sirona-inc-xray-2026-05-12/

DENTSPLY SIRONA Inc. $XRAY Shares Acquired by First Eagle Investment Management LLC

First Eagle Investment Management LLC increased its stake in DENTSPLY SIRONA Inc. by 3.2% in the fourth quarter, bringing its total holdings to 14.64 million shares valued at approximately $167.3 million. This increase comes as other institutional investors have also adjusted their positions in the medical instruments supplier. DENTSPLY SIRONA recently reported Q1 earnings with EPS slightly below estimates but revenue exceeding expectations, and has provided guidance for FY 2026 EPS.

https://www.marketbeat.com/instant-alerts/filing-dentsply-sirona-inc-xray-shares-acquired-by-first-eagle-investment-management-llc-2026-05-12/

Is Dentsply Sirona (XRAY) Now Offering Value After A 28% One Year Share Price Slide

Dentsply Sirona (XRAY) has experienced significant share price declines over the past year, three years, and five years, leading Simply Wall St to assess its current valuation. Using Discounted Cash Flow (DCF) and Price-to-Sales (P/S) ratio analyses, the stock appears significantly undervalued, with a DCF model suggesting a 64.9% discount and its P/S ratio being well below industry averages. The article also presents contrasting narratives for Dentsply Sirona's future, ranging from a "durability story" justifying a higher fair value to a more cautious view emphasizing competition and cost pressures.

https://www.sahmcapital.com/news/content/is-dentsply-sirona-xray-now-offering-value-after-a-28-one-year-share-price-slide-2026-05-09

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Solana ($SOL) Crypto Forecast: Down 5.6% Today

DENTSPLY SIRONA Inc. Price History

18.02.2026 - XRAY Stock was down 5.3%

• The stock price of XRAY declined despite a 5.24% increase on March 17.
• The FDA clearance for the MAGNETOM Free.Max Dental Edition, a new innovation, might not have led to immediate revenue growth, potentially disappointing investors.
• Despite increased stakes from investment firms like Invenomic Capital Management LP and Crawford Investment Counsel Inc., the stock's downward trend continues, possibly due to missed earnings expectations.
• The undervaluation of XRAY according to Simply Wall St's valuation model could offer an opportunity for investors, but market challenges and a multi-year share price slump may be contributing to the bearish movement.

21.03.2026 - XRAY Stock was down 0.9%

• The decline in Dentsply Sirona Inc.'s stock (XRAY) today may be linked to the recent upgrade by Citigroup, which raised the company's rating to a "strong sell," indicating negative sentiment towards its stock performance.
• Despite the company's significant presence in the dental sector and its focus on generating recurring revenue from essential dental products, lower-than-expected FY2026 guidance and missed EPS estimates might have contributed to the stock's downward trend.
• Investors could be reacting to Citi's reiterated Sell rating and target price of $10, reflecting a lack of confidence in Dentsply Sirona's stock performance in the short run.
• Market movements may also be influenced by concerns over factors like market consolidation, supply chain risks, and competition, despite the company's leading position in dental consumables and digital dentistry.

01.03.2026 - XRAY Stock was up 5.0%

• Despite negative analysis pointing out declining revenue and shaky fundamentals, the stock saw a significant bullish movement, possibly due to the increased price target, indicating a more optimistic outlook on its future performance.
• The administrative disclosure of Vanguard's 0% ownership in XRAY may have initially raised concerns, but the market sentiment seemed to have shifted positively towards the stock.
• The introduction of a new dental product by Dentsply Sirona USA may have also contributed to the bullish movement, showcasing potential for innovation and growth in the company's product line.
• Investors might be viewing the stock differently, possibly considering the potential of new investments and products to drive future growth, leading to the bullish market movement despite previous concerns.

19.02.2026 - XRAY Stock was down 5.1%

• The bearish movement in XRAY stock could be attributed to profit-taking by investors after a recent uptick in the stock price.
• Despite positive sentiments from analysts and figures like Jim Cramer, the market may have reacted negatively to the uncertainty surrounding the immediate revenue impact of the newly FDA-cleared dental MRI technology.
• The filing of 13G by Southpoint indicating a significant ownership stake in Dentsply Sirona might have also influenced market sentiment, leading to some selling pressure on the stock.
• Investors might be cautious about the company's ability to navigate existing market challenges and translate innovative technologies like the dental-dedicated MRI system into tangible revenue growth in the short term.

08.04.2026 - XRAY Stock was down 5.2%

• A reduction in DENTSPLY SIRONA's price target to $14 from $16 by Mizuho, highlighting ongoing margin constraints and market softness, likely influenced the stock's decline.
• The company's Q1 earnings call transcript, which exposed an EPS shortfall and external pressures, despite efforts to implement a "return to growth" strategy, could have further eroded investor confidence.
• The timely and effective execution of the company's growth and restructuring plan is imperative in restoring investor trust and market stability, as noted in the discourse surrounding the company.
• The company's Q1 2026 net loss, amplified research and development expenditures, restructuring outlays, and legal hurdles suggest a phase of strategic adaptations and intensified operational focus, possibly exerting a negative influence on investor sentiment and stock performance.

15.04.2026 - XRAY Stock was down 5.7%

• The decline in Dentsply Sirona's stock (XRAY) today is linked to the earnings miss in Q1, despite surpassing revenue expectations.
• The market's negative response to the revised FY guidance is due to the company reducing its EPS outlook for the full year, suggesting potential challenges ahead.
• A rise in wholesale inflation to 6% annually as shown in the April PPI report has impacted healthcare companies like Dentsply Sirona, increasing operating costs and raising concerns about possible regulatory actions on drug pricing.
• Despite a significant drop in the stock price over the past year, assessments of the company's value indicate Dentsply Sirona may be undervalued, offering a different perspective on its future prospects.

26.02.2026 - XRAY Stock was up 5.5%

• Anticipated weaker earnings by Zacks Research contrast with the launch of the new Vortex Blue Rotary Endo Files by DENTSPLY SIRONA, likely boosting investor confidence in the company's future offerings.
• Diverse analyst opinions and recent financial results may have led to stock price instability, partially offset by insider purchases indicating internal positivity and influencing investor optimism.
• The stock's bullish momentum today might be attributed to investors focusing on the growth potential of the new product rather than short-term earnings, potentially propelling the stock price upwards.

17.02.2026 - XRAY Stock was up 5.9%

• The positive market sentiment surrounding the FDA clearance for the MAGNETOM Free.Max Dental Edition may have influenced the bullish movement in XRAY's stock today, showcasing the company's dedication to innovation in the dental industry.
• Increased investments by notable entities like Invenomic Capital Management LP and company insiders purchasing shares could have boosted market confidence, indicating a positive outlook for XRAY's future performance.
• Despite recent earnings falling below expectations and a decline in share price over several years, the belief that XRAY is undervalued and the growth prospects in the dental sector may have attracted investor attention, contributing to the stock's bullish performance today.
• The accumulation of favorable developments in innovation, heightened investor confidence, and the perceived undervaluation could have collectively driven XRAY's strong bullish performance in the market today.

13.04.2026 - XRAY Stock was down 5.1%

• UBS Group AG and First Eagle Investment Management LLC have increased their holdings in DENTSPLY SIRONA Inc., displaying confidence in the firm's long-term viability.
• Vanguard Group Inc. has scaled back its position in the company, potentially indicating a more cautious stance on XRAY's future performance.
• The company's recent financial results, with earnings per share slightly lower than anticipated but revenue surpassing expectations, may have influenced the bearish sentiment as investors evaluate its growth prospects.
• The differing viewpoints on DENTSPLY SIRONA's valuation and future prospects could have contributed to market uncertainty, leading to the downward movement in the stock.

14.03.2026 - XRAY Stock was up 6.1%

• The bullish movement in XRAY stock today can be attributed to several factors:
• The unveiling of the scientific program and masterclasses for the Implant Solutions World Summit 2026 by Dentsply Sirona showcases the company's commitment to advancing implant dentistry through collaboration and innovation, boosting investor confidence in its future growth prospects.
• The projected growth of the global dental laboratories market, where Dentsply Sirona is a key player, indicates a positive outlook for the company's revenue and market position, driven by increasing prevalence of dental disorders and technological advancements.
• Despite a poor technical rating in the analysis, the stock presents a "nice setup opportunity" with recent consolidation and reduced volatility, potentially attracting short-term investors looking for entry points.
• Dentsply Sirona's focus on high-margin dental consumables and its resilient position in the healthcare sector make it an appealing option for investors seeking defensive exposure, especially amidst economic uncertainties and competitive pressures.

17.03.2026 - XRAY Stock was up 5.1%

• Despite a sell recommendation by one source, XRAY experienced a bullish movement likely due to the positive impact of a substantial acquisition of shares by a prominent entity.
• The increased stake by the entity, along with insider buying activity, may have instilled confidence in investors regarding the company's growth potential, counteracting the negative analyst outlook.
• The mixed signals from analysts and insider activity have created a scenario where investors are weighing the sell recommendation against the undervaluation of XRAY, leading to the bullish market movement today.
• This demonstrates the complexity of stock evaluation, where differing opinions and actions by institutional investors can drive market movements in unexpected directions.

04.04.2026 - XRAY Stock was down 3.4%

• The bearish movement in XRAY stock today could be attributed to several factors:
• Despite being viewed favorably by Ariel Investments and analysts, the recent price target cut from $15 to $13 might have raised concerns among investors.
• The slight miss on quarterly EPS, coupled with the company setting FY2026 EPS guidance lower than expected, could have led to a loss of confidence in XRAY's short-term performance.
• The significant passive investment stake held by Vanguard, while indicating long-term commitment, might have also created uncertainty in the market, contributing to the bearish trend.
• Overall, the market sentiment towards XRAY today seems to have been influenced by a combination of financial performance, analyst ratings, and institutional ownership, leading to the bearish movement in the stock.